Table 8. Cost results breakdown–per member per month (ABA-1L vs. ABA-2L+).

	ABA-1L	Abatacept 2L+	Incremental costs (ABA-1L –ABA-2L+)
Total costs per PMPM
bDMARD	71,722	72,156	-435
Concomitant medication	2,153	1,966	187
Monitoring	19,489	19,489	0
AEs occurring ≥5%	21	0	21
SAEs	3,699	3,446	253
Hospitalisations due to infections	439	384	55
Total	97,522	97,441	81

1L, first line; 2L+, second or later line; ABA, abatacept; AE, adverse event; bDMARD, biological disease-modifying antirheumatic drug; PMPM, per member per month; SAE, serious AE.